Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data ZyVersa Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Research and development
5.41
3.21
1.78
1.11
General and administrative
7.61
11.2
7.36
5.73
Operating expenses
13
108
9.14
25.5
Operating income
-13
-108
-9.14
-25.5
Pre-tax income
-14
-108
-9.41
-25.8
Income tax
-9.46
0.01
-0.85
Net income
-14
-98.3
-9.41
-25
EBITDA
-13
-108
-9.13
EPS, basic
-9.90
-1,090.00
-8.48
-4.18
EPS, diluted
-9.90
-1,090.00
-8.48
-4.18
Shares, basic (weighted)
2.42
0.1
1.11
5.96
Shares, diluted (weighted)
2.42
0.1
1.11
5.96
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
0.7
3.14
1.53
0.1
Other current assets
0.22
0.18
0.35
Total current assets
3.35
1.72
0.46
Property, plant and equipment
0.01
Lease right-of-use assets
0.01
Other non-current assets
18.6
18.6
Total assets
22.1
20.6
0.46
Accounts payable
8.43
9.34
10.1
Accrued liabilities
1.75
1.89
2.73
Total current liabilities
10.2
11.2
12.9
Total liabilities
11
12.1
12.9
Paid-in capital
114
121
125
Retained earnings
-103
-113
-138
Treasury stock
-0.01
-0.01
-0.01
Shareholders' equity
99.7
11.1
8.52
-12.4
Total equity
99.7
11.1
8.52
-12.4
Total liabilities and equity
22.1
20.6
0.46
Shares outstanding
0.4
2.51
8.1
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-14
-98.3
-9.41
-25
Depreciation and amortization
0.01
0.01
0.01
Stock-based compensation
3.52
1.19
0.71
0.22
Deferred income tax
-9.48
0.01
-0.85
Change in payables
6.62
2.41
0.89
0.69
Cash from operations
-1.49
-8.72
-7.52
-5.11
Stock issued
1.35
Cash from financing
1.87
5.96
5.91
3.69
Net change in cash
0.37
-2.76
-1.61
-1.43
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.10 on September 29, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-3,299.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-245.4%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-97.8%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
437.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
35.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.05x
Current assets / current liabilities.
Quick ratio
0.02x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.02x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.51
Cash from operations / diluted weighted shares.
Book value per share
-$1.74
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-3,055.0%
Net income / market cap (the inverse of P/E).
Was ZyVersa Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $25.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.